w w w . g. u z y u a n . c. n ...

Financial Performance - Total operating revenue for the first half of 2024 increased by 5.59% compared to the same period last year, reaching ¥284,137.44 million[3] - Net profit attributable to shareholders of the listed company rose by 28.12% year-on-year, amounting to ¥72,621.18 million[3] - Basic earnings per share increased by 28.12% to ¥0.37[3] - The net profit excluding non-recurring gains and losses increased by 29.43% to ¥72,363.45 million[3] Assets and Equity - Total assets at the end of the reporting period grew by 6.74% to ¥1,514,444.23 million[3] - The company's equity attributable to shareholders increased by 5.02% to ¥1,031,575.13 million[3] - The number of shares outstanding increased by 20.00% to 197,737.14 million shares[3] Profitability and Efficiency - The weighted average return on equity improved by 1.10 percentage points to 7.34%[3] - The company reported improved profit margins due to better control of product pricing and cost management[5] Reporting Integrity - There are no uncertainties affecting the accuracy of this performance report[5]

Financial Performance - The company's operating revenue for Q1 2024 was CNY 1,221,955,159.91, representing a decrease of 5.42% compared to the same period last year[3]. - Net profit attributable to shareholders was CNY 316,673,978.07, an increase of 20.91% year-on-year[3]. - The net profit after deducting non-recurring gains and losses was CNY 313,481,082.28, reflecting a growth of 23.82% compared to the previous year[3]. - Basic earnings per share were CNY 0.19, up by 20.91% year-on-year[3]. - Net profit for Q1 2024 reached CNY 432,127,203.32, an increase of 20.4% from CNY 358,982,561.98 in Q1 2023[14]. - Total comprehensive income for the first quarter of 2024 reached ¥432,127,203.32, an increase from ¥358,982,561.98 in the same period of 2023, representing a growth of approximately 20.3%[15]. - Basic and diluted earnings per share for the first quarter of 2024 were both ¥0.19, up from ¥0.16 in the first quarter of 2023, indicating a 18.75% increase[15]. Cash Flow and Liquidity - The net cash flow from operating activities decreased by 24.47% to CNY 468,822,105.59[3]. - Net cash flow from operating activities for the first quarter of 2024 was ¥468,822,105.59, a decrease of 24.4% compared to ¥620,695,486.70 in the first quarter of 2023[20]. - Cash received from sales of goods and services was ¥1,348,247,790.31, down from ¥1,417,650,581.55 in the previous year, reflecting a decline of about 4.9%[17]. - The company reported a net cash outflow from investing activities of ¥783,213,723.82 in the first quarter of 2024, compared to a net outflow of ¥201,374,271.14 in the same period of 2023[20]. - The company's total operating cash outflow for the first quarter of 2024 was ¥917,791,804.00, an increase from ¥825,867,376.18 in the first quarter of 2023, reflecting a rise of about 11.1%[20]. - Cash and cash equivalents at the end of the first quarter of 2024 were ¥2,516,181,677.81, down from ¥2,607,475,607.64 at the end of the first quarter of 2023, a decrease of approximately 3.5%[20]. - The company reported a net cash outflow from investing activities of CNY -530,984,145.37 in Q1 2024, compared to a net inflow of CNY 130,561,428.59 in Q1 2023[29]. - Cash and cash equivalents at the end of Q1 2024 totaled CNY 1,235,145,691.04, down from CNY 1,574,677,634.17 at the beginning of the quarter[29]. Assets and Liabilities - Total assets at the end of the reporting period were CNY 14,791,832,209.53, an increase of 4.26% from the end of the previous year[3]. - Total assets as of March 31, 2024, amounted to CNY 14,791,832,209.53, compared to CNY 14,188,056,936.91 at the end of 2023[10]. - Total liabilities increased to CNY 1,605,335,028.99 as of March 31, 2024, from CNY 1,433,686,959.69 at the end of 2023[11]. - The total liabilities and equity of the company as of Q1 2024 amounted to CNY 7,518,196,750.95, an increase from CNY 7,322,511,079.97 in the previous year[24]. - Total liabilities increased to ¥2,277,340,567.52 as of March 31, 2024, compared to ¥2,072,311,684.82 at the end of 2023, marking an increase of about 9.9%[23]. Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 48,217[6]. - The largest shareholder, China National Biotechnology Group Corporation, holds 45.64% of the shares[6]. - Shareholders' equity attributable to the parent company was CNY 10,139,253,146.61, up by 3.22% compared to the previous year[3]. - The total equity attributable to shareholders reached CNY 10,139,253,146.61 as of March 31, 2024, up from CNY 9,822,579,168.54 at the end of 2023[11]. - The company’s total equity remained stable at ¥5,240,856,183.43 as of March 31, 2024, compared to the previous period, indicating no significant changes in shareholder equity[23]. Expenses and Investments - Total operating costs for Q1 2024 were CNY 722,799,366.81, down 18.2% from CNY 883,395,917.16 in Q1 2023[13]. - Research and development expenses for Q1 2024 were CNY 24,452,750.69, significantly higher than CNY 9,539,026.33 in Q1 2023[14]. - The company incurred financial expenses of CNY -2,340,557.92 in Q1 2024, a significant decrease from CNY 734,344.11 in Q1 2023[25]. - The company reported investment income of CNY 10,234,166.63 in Q1 2024, up from CNY 8,437,500.00 in Q1 2023, representing an increase of about 21.3%[25]. - The company’s management expenses rose to CNY 24,025,374.33 in Q1 2024, compared to CNY 20,709,858.21 in Q1 2023, reflecting an increase of approximately 15.5%[25].

证券代码：600161 证券简称：天坛生物 公告编号：2024-018 北京天坛生物制品股份有限公司 关于所属企业获得药品补充申请批准通知书并通过药品 GMP 符合性检查公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大 遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 北京天坛生物制品股份有限公司所属成都蓉生药业有限责任公司（以下简称"成都蓉 生"）于近日收到国家药品监督管理局签发的《药品补充申请批准通知书》，成都蓉生研制 的"人纤维蛋白原"符合药品注册的相关要求。同时，成都蓉生相关生产场地已通过药品 GMP 符合性检查，并获得了四川省药品监督管理局签发的《药品 GMP 现场检查结果通知书》 （川 2022105）。具体情况如下： 一、 概况 （一） 产品信息 *注：上述国内市场情况来自国家药品监督管理局官方网站（http://www.nmpa.gov.cn）。 二、 《药品 GMP 现场检查结果通知书》主要内容 企业名称：成都蓉生药业有限责任公司 药品生产许可证编号：川 20160165 检查地址：四川省成都市双流区菁园路 280 号 检查范围：血液制品（人纤维蛋白原） ...

证券代码：600161 证券简称：天坛生物 公告编号：2024-017 北京天坛生物制品股份有限公司 关于所属企业获得药物临床试验批准通知书公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 近日，北京天坛生物制品股份有限公司所属国药集团武汉生物制药有限公司 获得国家药品监督管理局签发的《药物临床试验批准通知书》，同意国药集团武 汉生物制药有限公司开展"人凝血酶原复合物"临床试验。现将有关信息披露如 下： 一、概况 （一） 产品信息 | 产品 | | 适应症 | 获得受理的时 | 规格 | 注册分类 | 剂型 | 研发 | | --- | --- | --- | --- | --- | --- | --- | --- | | 名称 | | | 间及受理号 | | | | 投入 | | | | 本品主要用于治疗先天性和获得性 | | | | | | | | | 凝血因子II、VII、IX和X缺乏症（单 | | | | | | | | | 独或联合缺陷）包括： | | | | | | | | | 1.凝血因子II、VII、IX和 ...

Financial Performance - The total revenue for the fourth quarter was CNY 1,158,439,298.71, with a total annual revenue of CNY 5,180,440,000.00[16] - The net profit attributable to shareholders for the fourth quarter was CNY 222,488,189.96, with an annual net profit of CNY 1,109,988,000.00[17] - The company's operating revenue for 2023 reached ¥5,180,441,799.76, representing a year-on-year increase of 21.57% compared to ¥4,261,304,622.88 in 2022[22] - The net profit attributable to shareholders for 2023 was ¥1,109,888,597.22, an increase of 25.99% from ¥880,916,474.36 in 2022[22] - The net cash flow from operating activities for 2023 was ¥2,393,576,031.26, showing a significant increase of 112.57% compared to ¥1,126,002,190.03 in 2022[22] - The company achieved an annual revenue of 5,180.44 million yuan, representing a year-on-year growth of 21.57%[25] - The net profit for the year was 1,509.46 million yuan, with a year-on-year increase of 25.30%[25] Dividends and Shareholder Returns - The company plans to distribute a cash dividend of CNY 1.5 per 10 shares, totaling CNY 247,171,430.70, and to increase capital by 2 shares for every 10 shares held, resulting in an increase of 329,561,908 shares[4] - The net profit attributable to ordinary shareholders of the listed company for the consolidated financial statements is 1,109,888,597.22 RMB, with the dividend amount representing 22.27% of this net profit[139] Operational Highlights - The company launched the fourth-generation 10% concentration intravenous immunoglobulin, becoming the first in the domestic market to receive approval[25] - Plasma collection reached 2,415 tons, marking an 18.67% year-on-year increase, maintaining a leading position in the industry[26] - The company completed the construction and operational launch of several production facilities, enhancing its production capacity[30] - The company secured 22 authorized patents during the reporting period, including 7 invention patents[25] - The company has expanded its operational plasma stations to 80, enhancing its blood source capabilities[26] Market and Industry Position - The company maintains a leading position in the domestic blood product market, with a production history dating back to 1966 and a market share that includes 15 varieties and 74 production licenses for blood products[44] - The blood products industry is characterized by high entry barriers, with stringent regulations on raw plasma collection and production operations[39] - The number of blood product manufacturers in China has decreased to less than 30, with approximately 17 major groups remaining after consolidation[38] - The market share of the top five global blood product companies accounts for 80%-85%, indicating a high level of industry concentration[38] Research and Development - The company has over 100 research personnel and is actively developing more than ten new blood products and gene recombinant products, maintaining a leading position in R&D within the industry[45] - The company has established a comprehensive R&D quality management system to enhance the quality of new product development throughout its lifecycle[45] - The company emphasizes technological innovation and has established a dedicated R&D center to enhance product development[48] - The company has implemented a group-based R&D model to accelerate the development and commercialization of new products, reducing R&D time[45] Compliance and Governance - The company has implemented a robust corporate governance structure, ensuring compliance with legal and regulatory requirements, and protecting shareholder rights[108] - The board of directors consists of 9 members, including 3 independent directors, ensuring a balanced governance structure[109] - The company has established performance evaluation standards for senior management, linking compensation to company performance to enhance operational efficiency[110] - The company maintains transparency in information disclosure, ensuring all shareholders, especially minority shareholders, have equal access to company information[110] Environmental and Social Responsibility - The company invested approximately 16.49 million yuan in environmental protection during the reporting period[143] - The company’s subsidiary Chengdu Rongsheng was included in the list of key pollutant discharge units by the Chengdu Ecological Environment Bureau in 2023[144] - The company has committed to avoiding competition with its controlling shareholder, China National Biological, ensuring no overlap in core business areas[166] - The company has actively engaged in various social responsibility initiatives, enhancing its role in community support and development[165] Future Outlook - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 25%[116] - The company is focused on innovation in the biopharmaceutical sector, but new product development carries inherent risks due to long development cycles and high investment requirements[106] - The company plans to enhance its compliance and risk management frameworks to support its growth strategy[117]

北京天坛生物制品股份有限公司 2023 年度独立董事述职报告 本人方燕，作为北京天坛生物制品股份有限公司（以下简称"公 司"或"天坛生物"）的独立董事，2023年度，按照《公司法》《证券 法》《上市公司独立董事管理办法》《上海证券交易所股票上市规则》 和《公司章程》等有关规定，勤勉尽责，忠实的履行了独立董事的职 责。现将2023年度履职情况报告如下： 一、 独立董事的基本情况 方燕：历任北京市公安局党校教师；北京元亨律师事务所合伙人； 陕西省国际信托投资股份有限公司法律处副处长。现任北京金诚同达律 师事务所高级合伙人、西安分所主任；全国人大代表；中华全国律师协 会理事会理事；陕西省律师协会副会长、党委委员；最高人民法院特约 监督员；最高人民检察院特约监督员；全国人大副委员长直接联系代 表；北京天坛生物制品股份有限公司独立董事。 本人任职符合《上市公司独立董事管理办法》第六条规定的独立性 要求，不存在影响独立性的情况。 二、 独立董事年度履职概况 (一) 出席2023年度董事会和股东大会会议情况 2023年度，公司共召开董事会会议9次、股东大会2次。本人作为独 立董事亲自出席董事会会议8次、委托出席董事会会议1 ...

公司代码：600161 公司简称：天坛生物 公司内部控制的目标是合理保证经营管理合法合规、资产安全、财务报告及相关信息真实完整，提 高经营效率和效果，促进实现发展战略。由于内部控制存在的固有局限性，故仅能为实现上述目标提供 合理保证。此外，由于情况的变化可能导致内部控制变得不恰当，或对控制政策和程序遵循的程度降低， 根据内部控制评价结果推测未来内部控制的有效性具有一定的风险。 二. 内部控制评价结论 1. 公司于内部控制评价报告基准日，是否存在财务报告内部控制重大缺陷 北京天坛生物制品股份有限公司 2023 年度内部控制评价报告 北京天坛生物制品股份有限公司全体股东： 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称企业内部 控制规范体系），结合本公司（以下简称公司）内部控制制度和评价办法，在内部控制日常监督和专项 监督的基础上，我们对公司2023年12月31日（内部控制评价报告基准日）的内部控制有效性进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露内 部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部 ...

北京天坛生物制品股份有限公司 2023 年度募集资金年度存放与使用情况鉴证报告 目 录 一、募集资金年度存放与使用情况鉴证报告………………………第 1—2 页 二、关于募集资金年度存放与使用情况的专项报告………………第 3—7 页 我们的责任是在实施鉴证工作的基础上对天坛生物公司管理层编制的上述 报告独立地提出鉴证结论。 三、执业资质证书………………………………………………… 第 8—11 页 募集资金年度存放与使用情况鉴证报告 天健审〔2024〕1-130 号 北京天坛生物制品股份有限公司全体股东： 我们鉴证了后附的北京天坛生物制品股份有限公司（以下简称天坛生物公司） 管理层编制的 2023 年度《关于募集资金年度存放与使用情况的专项报告》。 一、对报告使用者和使用目的的限定 本鉴证报告仅供天坛生物公司年度报告披露时使用，不得用作任何其他目的。 我们同意将本鉴证报告作为天坛生物公司年度报告的必备文件，随同其他文件一 起报送并对外披露。 二、管理层的责任 天坛生物公司管理层的责任是提供真实、合法、完整的相关资料，按照《上 市公司监管指引第 2 号——上市公司募集资金管理和使用的监管要求（2022 年 修订）》 ...

每股转增 0.2 股。 本次利润分配及资本公积转增股本以实施权益分派股权登记日登记的总 股本为基数，具体日期将在权益分派实施公告中明确。 证券代码：600161 证券简称：天坛生物 公告编号：2024-010 北京天坛生物制品股份有限公司 2023 年度利润分配及资本公积转增股本预案公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 每股分配比例，每股转增比例 每股派发现金红利 0.15 元（含税）； 在实施权益分派的股权登记日前公司总股本发生变动的，公司拟维持分配 总额和每股转增比例不变，相应调整每股分配比例和转增总额，并将在相关公告 中披露。 本年度现金分红比例低于 30%的简要原因说明：公司《2023 年年度利润分 配及资本公积转增股本预案》为考虑公司发展需要，并结合公司资金需求制定， 本次利润分配后留存未分配利润主要用于日常经营。 一、 利润分配预案内容 经天健会计师事务所（特殊普通合伙）审计，截至 2023 年 12 月 31 日，公 司期末可供分配利润为人民币 278,577,237.86 元。经 ...